FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Kuros Biosciences AG Stock AnalysisComprehensive stock analysis for Kuros Biosciences AG (CSBTF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCSBTF
CSBTF
Kuros Biosciences AG
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CSBTF
Home🔹Stocks🔹Kuros Biosciences AG

Kuros Biosciences AG

CSBTF•OTC

Kuros Biosciences AG

CSBTF•OTC
Market cap
$1.25B
Sentiment

Your view on CSBTF

Mkt Cap
$1.25B
Sentiment
Your view
CSBTF
Kuros Biosciences AG
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CSBTF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Kuros Biosciences AG

Industry
Biotechnology
Sector
Healthcare
CEO
Christopher T. Fair
Headquarters
Wagistrasse 25, Schlieren, CH
Industry
Biotechnology
Sector
Healthcare
CEO
Christopher T. Fair
Headquarters
Wagistrasse 25, Schlieren, CH
Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News